Статья
Проблема приверженности к терапии в кардиологии
В обзорной статье приведены результаты исследований по оценке приверженности к медикаментозной терапии пациентов после выписки из стационара: проанализированы причины отсутствия приверженности, оценено влияние приверженности на ближайшие и отдаленные результаты хирургического и медикаментозного лечения, структурированы способы повышения приверженности к терапии, а также экономические аспекты.
1. Santo K., Kirkendall S., Laba T. L. et al. Interventions to improve medication adherence in coronary disease patients: A systematic review and meta-analysis of randomised controlled trials. Eur J Prev Cardiol 2016;23 (10):1065-1076. DOI: 10.1177/2047487316638501.
2. Sabate E., World H. O. WHO Adherence to Long Term Therapies Project, Global Adherence IN. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization 2003.
3. Baroletti S and Dell'Orfano H. Medication adherence in cardiovascular disease. Circulation 2010;121:1455-1458. DOI: 10.1161 /CIRCULATIONAHA. 109.904003.
4. Rodriguez F. C. C., Steg P. G., Kubhani D. J. et al. Predictors of longterm adherence to evidence-based cardiovascular disease medications in outpatient with stable atherotrombotic disease: findings from the REACH Registry. Clin Cardiol 2013;16:721-727. DOI: 10.1002/clc. 22217.
5. Yusuf S., Islam S., Chow C. K. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-1243. DOI: 10.1016/S0140-6736 (11) 61215-4.
6. Hauptman P.J. Medication adherence in heart failure. Heart Fail Rev 2008;13:99-106. DOI: 10.1007/s10741-007-9020-7.
7. Leventhan M.J., Riegel B., Carlson B., De Geest S. Negotiating compliance in heart failure: remaining issues and questions. EurJ Cardiovasc Nurs 2005;4:298-307. DOI: 10.1016/j.ejcnurse. 2005.04.001.
8. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23 (8):1296-310. DOI: 10.1016/S0149-2918 (01) 80109-0.
9. Ho P. M., Rumsfeld J. S., Masoudi F. A. et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166 (17):1836-1841. DOI: 10.1001/ archinte. 166.17.1836.
10. Chowdhury R., Khan H., Heydon E. et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur HeartJ 2013;34 (38):2940-2948. DOI: 10.1093/eur-heartj/eht295.
11. Corrao G., Rea F., Ghirardi A. et al. Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice. Hypertension 2015;66 (4):742-749. DOI: 10.1161/ HYPERTENSIONAHA. 115.05463.
12. Petrilla A. A., Benner J. S., Battleman D. S. et al. Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medication. IntJ Clin Pract 2005;59 (12):1441-1451. DOI: 10.1111/j. 1368-5031.2005.00704. x.
13. Sever P. S., Dahlöf B., Poulter N. R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003;361:1149-1158. DOI: 10.1016/S0140-6736 (03) 12948-0.
14. Armstrong E. J., Chen D. C., Westin G. G. et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc 2014;3 (2):e000697. DOI: 10.1161/JAHA. 113.000697.
15. Ho P. M., SpertusJ. A., Masoudi F. A. et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842-1847. DOI: 10.1001/archinte. 166.17.1842.
16. Bell C. M. B. S., Gunraj N., Huo C. et al. Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. JAMA 2011;306:840-847. DOI: 10.1001/jama. 2011.1206.
17. Jackevicius C. A., Li P., Tu J. V. Prevalence, predictors, and outcomes ofprimary non-adherence after acute myocardial infarction. Circulation 2008;117:1028-1036. DOI: 10.1161/circulationaha. 107.706820.
18. Rasmussen J. N., Chong A., Alter D. A. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177-186. DOI: 10.1001/jama. 297.2.177.
19. Allonen J., Nieminen M. S., Lokki M. et al. Mortality rate increases steeply with non-adherence to statin therapy in patients with acute coronary syndrome. Clin Cardiol 2012;35: E22-7. DOI: 10.1002/clc. 22056.
20. Kurlansky P., Herbert M., Prince S., Mack M. Coronary Artery Bypass Graft Versus Percutaneous Coronary Intervention: Meds Matter: Impact of Adherence to Medical ^erapy on Comparative Outcomes. Circulation 2016;134 (17):1238-1246. DOI: 10.1161/ CIRCULATIONAHA. 115.021183.
21. Mehran R., Baber U., Steg P. G. et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382:1714-1722. DOI: 10.1016/S0140-6736 (13) 61720-1.
22. Iakovou I., Schmidt T., Bonizzoni E. et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130. DOI: 10.1001/jama. 293.17.2126.
23. Collet J. P., Montalescot G., Steg P. G. et al. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis 2009;102:485-496. DOI: 10.1016/j. acvd. 2009.03.012.
24. Granger B. B. S. K., Ekman I., Granger C. B. et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: doubleblind, randomised, controlled clinical trial. Lancet 2005;366:2005-2011. DOI: 10.1016/S0140-6736 (05) 67760-4.
25. Steg P. G., Harrington R. A., Emanuelsson H. et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 2013;128:1055-1065. DOI: 10.1161/ CIRCULATIONAHA. 113.002589.
26. Serebruany V., Rao S. V., Silva M. A. et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J. 2009;2:227-235. DOI: 10.1093/eurheartj/ehp434.
27. Wouters H., Van Dijk L., Geers H. C. J. et al. Understanding Statin Non-Adherence: Knowing Which Perceptions and Experiences Matter to Different Patients. PLoS ONE 2016;11 (1): e0146272. DOI: 10.1371 /journal. pone. 0146272.
28. Kassab Y., Hassan Y., Abd Aziz N. et al. Patients' adherence to secondary prevention pharmacotherapy after acute coronary syndromes. Int J. Clin Pharm 2013;35:275-280. DOI: 10.1007/s11096-012-9735-y.
29. Melloni C., Alexander K. P., Ou F. S. et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. AmJ Cardiol 2009;104:175-181. DOI: 10.1016/j. amjcard. 2009.03.013.
30. Thom S., Poulter N., Field J. et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD : the UMPIRE randomized clinical trial. JAMA 2013;310:918-929. DOI: 10.1001/jama. 2013.277064.
31. Ruxin J., Paluzzi J. E., Wilson P. A. et al. Emerging consensus in HIV/AIDS, malaria, tuberculosis, and access to essential medicines. Lancet 2005;365:618-621. DOI: 10.1016/S0140-6736 (05) 17914-8.
32. Jackevicius C. A., Mamdani M., Tu J. V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-467. DOI: 10.1001 /jama. 288.4.462.
33. Oates D. J., Paasche-Orlow M. K. Health literacy: communication strategies to improve patient comprehension of cardiovascular health. Circulation 2009;119:1049-1051. DOI: 10.1161/ CIRCULATIONAHA. 108.818468.
34. Kumbhani D.J., Fonarow G. C., Cannon C. P. et al. Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J. Med 2013;126:74 e71-e79. DOI: 10.1016/ j.amjmed. 2012.02.025.
35. Gukathasan N., Witzenbichler B., Weisz G. et al. Impact of gender of patterns of dual antiplatelet therapy cessation and nonadherence: one-year results from the patterns of non-adherence to anti-platelet regimens in stented patients (PARIS), an observational single-arm study.J. Am Coll Cardiol 2013;61: E1531. DOI: 10.1016/s0735-1097 (13) 61531-4.
36. Berry S. D., Quach L., Procter-Gray E. et al. Poor Adherence to Medications May Be Associated with Falls. J. Gerontol A BiolSci Med Sci 2010; 65A (5):553-558. DOI: 10.1093/gerona/glq027.
37. Glassman A. H., O'Connor C. M., Califf R. M. et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-709. DOI:10.1001/jama. 288.6.701
38. Weidenbacher H.J., Beadles C. A., Maciejewski M. et al. Extent and reasons for nonadherence to antihypertensive, cholesterol, and diabetes medications: the association with depressive symptom burden in a sample of American veterans. Patient Preference and Adherence 2015;9:327-336. DOI: 10.2147/PPA. S74531.
39. Kronish I. M., Edmondson D., Goldfinger J. Z. et al. Posttraumatic stress disorder and adherence to medications in survivors of strokes and transient ischemic attacks. Stroke 2012;43:2192-2197. DOI: 10.1161/STROKE AHA. 112.655209.
40. Williams L., O'Connor R. C., Grubb N., O'Carroll R. Type D. personality predicts poor medication adherence in myocardial infarction patients. Psychol Health 2011;26:703-712. DOI: 10.1080/ 08870446.2010.488265.
41. Britten N., Stevenson F. A., Barry C. A. et al. Misunderstandings in prescribing decisions in general practice: qualitative study. BMJ 2000;320:484-488. DOI: 10.1136/bmj. 320.7233.484.
42. Luders S., Schrader J., Schmieder R. E. et al. Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial. Europ J. Cardiovasc Prev Rehabil 2010; 17:271-279. DOI: 10.1097/HJR. 0b013e328330be62.
43. Hines R., Stone N.J. Patients and Physicians Beliefs and Practices Regarding Adherence to Cardiovascular Medication. JAMA Cardiol 2016;1 (4):470-473. DOI: 10.1001/jamacardio. 2016.0634.
44. Bourdes V., Ferrieres J., Amar J. et al. Prediction of persistence of combined evidence-based cardiovascular medications in patients with acute coronary syndrome after hospital discharge using neural networks. Med Biol Eng Comput 2011;49:947-955. DOI: 10.1007/s11517-011-0785-4.
45. Park L. G., Howie-Esquivel J., Chung M. L., Dracup K. A text messaging intervention to promote medication adherence for patients with coronary heart disease: a randomized controlled trial. Patient Educ Couns 2014;94 (2):261-268. DOI: 10.1016/j.pec. 2013.10.027.
46. Pomerantz J. M. Improving Medication Adherence: A New Marketing Opportunity for the Pharmaceutical Industry. Posted: 06/24/2004; 2004 Cliggott Publishing, Division of CMP Healthcare Media.
47. Derose S. F., Green K., Marrett E. et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Intern Med 2013;173:38-43. DOI: 10.1001/2013. jamainternmed. 717.
48. Lee J. K., Grace K. A., Taylor A. J. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006;296:2563-2571. DOI: 10.1001/jama. 296.21. joc60162.
49. Friedman R. H., Kazis L. E., Jette A. et al. A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. Am J. Hypert 1996;9:285-292. DOI: 10.1016/0895-7061 (95) 00353-3.
50. Rinfret S., Rodes-Cabau J., Bagur R. et al. Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation. Heart 2013;99:562-569. DOI: 10.1136/heartjnl-2012-303004.
51. Khonsari S., Subramanian P., Chinna K. et al. Effect of a reminder system using an automated short message service on medication adherence following acute coronary syndrome. Eur J. Cardiovasc Nurs 2015;14 (2):170-179. DOI: 10.1177/1474515114521910.
52. Clyne W., White S., McLachlan S. Developing consensus-based policy solutions for medicines adherence for Europe: a Delphi study. BMC Health Serv Res 2012;12:425. DOI: 10.1186/ 1472-6963-12-425.
53. Cheng K., Ingram N., Keenan J., Choudhury R. P. Evidence of poor adherence to secondary prevention after acute coronary syndromes: possible remedies through the application of new technologies. Open Heart 2015;2: e000166. DOI: 10.1136/ openhrt-2014-000166.
54. Обединский А. А., Курбатов В. П., Обединская Н. Р. и др. Влияние чрескожной транслюминальной коронарной ангиопластики при хронической окклюзии правой коронарной артерии на клинические характеристики и показатели стресс-МРТ в послеоперационном периоде. Патология кровообращения и кардиохирургия 2015;19:3:48-53.) http://dx.DOI.org/ 10.21688/1681-3472-2015-4-48-53.
55. Yasmin F., Banu B., Zakir S. M. et al. Positive influence of short message service and voice call interventions on adherence and health outcomes in case of chronic disease care: a systematic review. BMC Med Inform Decis Mak 2016;16:46. DOI: 10.1186/ s12911-016-0286-3